Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates | Zendy

Cristina JiménezOrtigosa | Zendy; Padmaja Paderu | Zendy; Mary Motyl | Zendy; David S. Perlin | Zendy

Open Access

Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates

Author(s) -

Cristina JiménezOrtigosa,

Padmaja Paderu,

Mary Motyl,

David S. Perlin

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02145-13

Subject(s) - echinocandin , echinocandins , potency , microbiology and biotechnology , aspergillus , in vitro , biology , fungi imperfecti , derivative (finance) , antifungal , amphotericin b , biochemistry , fluconazole , caspofungin , economics , financial economics

MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated thein vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in theFKS gene(s) ofCandida spp. andAspergillus spp. MK-3118 demonstrated enhanced efficacy for mostC. albicans andC. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50 s).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research